Cost-effectiveness of population screening for aortic stenosis.

Pouya MotazedianGraeme Prosperi-PortaBenjamin Hibbert Hawre J JalalMarino LabinazIan G BurwashOmar Abdel-RazekPietro Di SantoTrevor SimardGeorge A WellsDoug Coyle

Published in: European heart journal. Quality of care & clinical outcomes (2024)

Screening for AS at 80 years of age with a one-time TTE, in a Canadian population, improves quality of life and is cost-effective in a publicly funded healthcare system providing TAVR is reserved for symptomatic patients.

Keyphrases

aortic stenosis
ejection fraction
transcatheter aortic valve replacement
aortic valve replacement
aortic valve
transcatheter aortic valve implantation
end stage renal disease
left ventricular
newly diagnosed
chronic kidney disease
coronary artery disease
heart failure